PharmX Technologies (ASX:PHX) LT-Debt-to-Total-Asset : 0.01 (As of Dec. 2023)

View and export this data going back to 1973. Start your Free Trial

What is PharmX Technologies LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. PharmX Technologies's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.01.

PharmX Technologies's long-term debt to total assets ratio increased from Dec. 2022 (0.00) to Dec. 2023 (0.01). It may suggest that PharmX Technologies is progressively becoming more dependent on debt to grow their business.

PharmX Technologies LT-Debt-to-Total-Asset Historical Data

The historical data trend for PharmX Technologies's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmX Technologies LT-Debt-to-Total-Asset Chart

PharmX Technologies Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

PharmX Technologies Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	0.01

PharmX Technologies LT-Debt-to-Total-Asset Calculation

PharmX Technologies's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as

LT Debt to Total Assets (A: Jun. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Jun. 2023 )	/	Total Assets (A: Jun. 2023 )
	=	0	/	36.52
	=	0.00

PharmX Technologies's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	0.188	/	29.596
	=	0.01

PharmX Technologies (ASX:PHX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

PharmX Technologies LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of PharmX Technologies's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

PharmX Technologies (ASX:PHX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » PharmX Technologies Ltd (ASX:PHX) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

17 Castlereagh Street, Level 11, Sydney, NSW, AUS, 2000

Website

https://www.corumgroup.com.au

PharmX Technologies Ltd Formerly Corum Group Ltd is an Australia-based software and technology company. The company has a single segment which is Health Services. In Health services, the company develops and distributes business software for the pharmacy industry with particular emphasis on point-of-sale and pharmaceutical dispensing software, support services, and associated computer hardware. It derives a majority of its revenue from the Health services business. the company discontinued the e-commerce business in 2022.